



Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Tetsuhide Ito¹ · Takuji Okusaka² · Toshirou Nishida³ · Kenji Yamao⁴ · Hisato Igarashi¹ · Chigusa Morizane² · Shunsuke Kondo² · Nobumasa Mizuno⁴ · Kazuo Hara⁴ · Akira Sawaki^{4,5} · Satoshi Hashigaki⁶ · Nobuyuki Kimura⁶ · Mami Murakami^{6,7} · Emiko Ohki⁶ · Richard C. Chao⁸ · Masayuki Imamura⁹

Published online: 23 March 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to: Invest New Drugs (2013) 31:1265–1274
<https://doi.org/10.1007/s10637-012-9910-y>

In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.

The original article has been corrected.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10637-012-9910-y>

✉ Tetsuhide Ito
itopapa@intmed3.med.kyushu-u.ac.jp

¹ Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan

² Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

³ Department of Surgery, Osaka Police Hospital, Osaka, Japan

⁴ Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan

⁵ Present address: Nagoya Daini Red Cross Hospital, Nagoya, Japan

⁶ Pfizer Japan Inc., Tokyo, Japan

⁷ Present address: Drug Delivery and Formulation Group, Medicinal Chemistry Platform, Ontario Institute for Cancer Research, Toronto, ON, Canada

⁸ Pfizer Oncology, La Jolla, CA, USA

⁹ Kansai Electric Power Company Hospital, Osaka, Japan